Neoadjuvant systemic therapy in breast cancer: use and trends in radiotherapy practice

T.A. Koulis MD, K. Beecham MD, C. Speers, S. Tyldesley MD, D. Voduc MD, C. Simmons MD, and R. Olson MD

ABSTRACT

Background  The use of neoadjuvant systemic therapy (NAST) in the treatment of breast cancer is increasing, and the role of adjuvant radiation therapy (RT) in that setting is uncertain. We sought to review and report the use of NAST, its trends over time, and its relationship with the prescribing patterns of locoregional RT in a provincial cancer system.

Methods  Patients with stages I–III breast cancer diagnosed during 2007–2012 were identified using a provincial database. Patient, tumour, and treatment characteristics were extracted. Multivariable logistic regression analyses were used to assess associations with the use of NAST. Kaplan–Meier and Cox regression were used for survival analyses.

Results  Of the 11,658 patients who met the inclusion criteria, 602 (5%) had received NAST. Use of NAST was more frequent in stage III patients (53%) than in stages I and II patients (2%). In clinically lymph-node positive patients, a pathology assessment was made approximately 50% of the time. Higher clinical tumour stage and increasing clinical nodal stage predicted for increasing use of NAST and of nodal RT after NAST, but pathologic nodal status after NAST was not associated with use of nodal RT. A statistically significant survival difference was observed between patients in the NAST and no-NAST groups, but that significance disappeared in a multivariable Cox regression analysis.

Conclusions  This population-based study demonstrated 5% use of NAST for breast cancer. Most patients received nodal RT after NAST, and nodal RT was not associated with pathologic stage after NAST. Findings likely reflect the realities of clinical practice and show that reliance on clinical nodal staging results in outcomes similar to those reported in the literature.

Key Words  Breast cancer, neoadjuvant systemic therapies, radiotherapy, nodal irradiation, nodal staging

INTRODUCTION

Interest in and use of neoadjuvant systemic therapy (NAST) in breast cancer (BCa) has been increasing. The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 clinical trial demonstrated that neoadjuvant therapy was not superior to adjuvant chemotherapy for the primary endpoints of disease-free survival or overall survival (OS), but did appear to facilitate more breast-conserving surgery. As a result, although NAST was historically used to enable resection of otherwise unresectable or locally advanced BCa, it is increasingly used for less-advanced tumours to facilitate breast-conserving surgery. Other emerging uses of NAST include the study of novel systemic agents, enabling smaller studies to determine the activity of an agent in a shorter period of time.

The indications for regional radiotherapy (RT) after mastectomy in non-locally-advanced BCa have been based on nodal status (level 1 evidence). As NAST becomes more commonplace, standardization is needed in the delivery of adjuvant locoregional (LR) RT in this context. The lack of evidence in this setting has made such standardization difficult and could affect patient care and LR outcomes.

In the context of adjuvant systemic therapy, the addition of adjuvant LR RT lowers LR relapse rates. It also offers a BCa-free survival benefit in node-positive patients treated with either mastectomy or breast-conserving surgery and, in some trials, an OS advantage. The decision to offer LR RT has largely been based on the presence or number of positive axillary lymph nodes and tumour size, assessed before chemotherapy.

Although it seems logical to offer LR RT when nodal disease is identified after NAST, whether to offer LR RT when no nodal disease is detected after NAST is unclear, especially if the “clinically involved” nodes were not
pathologically sampled before systemic treatment. Diagnostic imaging—including ultrasonography, magnetic resonance imaging, or combined positron-emission tomography and computed tomography—does not have sufficient specificity or sensitivity to replace pathology assessment\(^{14,15}\). Several recent publications have shown a lower risk of recurrence after pathologic complete response; however, a pathologic complete response after neoadjuvant systemic therapy does not entirely eliminate the risk of recurrence\(^{16-19}\) [a question that is currently under examination (https://clinicaltrials.gov/ct2/show/NCT01872975)]. In the meantime, we sought to review and report on the use of neoadjuvant systemic therapy, its trends over time, and its relationship with the prescribing patterns of locoregional radiation therapy in a provincial cancer system.

**METHODS**

*Data Source and Extraction*

The BC Cancer Agency (bcca) is the sole provider of radiation therapy in British Columbia. Patients with nonmetastatic breast cancer diagnosed between July 2012 and June 2012 were identified through the Breast Cancer Outcomes Unit database, which prospectively records tumour, stage, treatment, and outcome data. The proportion of patients who received neoadjuvant systemic therapy as part of their initial therapy was determined. Prognostic and treatment factors were extracted from the Breast Cancer Outcomes Unit database, and the patient’s electronic medical chart was reviewed to determine additional information, including the method of lymph node assessment before neoadjuvant systemic therapy.

*Statistical Analysis*

Patient characteristics are presented as descriptive statistics, and the chi-square and Fisher exact tests were used to assess associations with the use of neoadjuvant systemic therapy, treatment facility, and year of treatment. Multivariable logistic regression analyses were used to assess the associations between variables and the subsequent use of neoadjuvant systemic therapy. All \( p \) values were 2-sided, and values less than 0.05 were considered statistically significant. Kaplan–Meier analysis was used to estimate overall survival (OS), locoregional relapse-free survival (LRRFS), and distant metastasis–free survival (DMFS), with OS being calculated from the date of diagnosis to date of death, LRRFS being calculated from the date of diagnosis to time to relapse in breast or regional lymph nodes as a first event, and DMFS being calculated from the date of diagnosis to the date of first metastatic event. Cox regression analysis was used to analyze the effect of risk factors on OS, LRRFS, and DMFS. The analyses were conducted using the SPSS software application (version 14.0: SPSS, Chicago, IL, U.S.A.). The study was approved by the bcca–University of British Columbia research ethics board.

**RESULTS**

*Overall Demographics*

During the study period, 11,658 patients were diagnosed and referred to the bcca with nonmetastatic breast cancer. Of those patients, 602 (5%) received neoadjuvant systemic therapy, 330 of whom (55%) were clinical stage III and 272 of whom (45%) were stages I–II. The neoadjuvant systemic therapy consisted mainly of chemotherapy (92%) as opposed to endocrine therapy. Table 1 summarizes the patient, tumour, and treatment characteristics.

**TABLE I** Patient, tumour, and treatment characteristics

| Characteristic | Received neoadjuvant systemic therapy | \( p \) Value |
|----------------|--------------------------------------|-------------|
| **Patients (n)** | 11,056 | 602 |
| Median age (years) | 61 | 53 | <0.001 |
| Menopausal status [n (%)] | 2947 (27) | 294 (49) | <0.001 |
| Receptor status [n (%)] | 9509 (86) | 434 (72) | <0.001 |
| Clinical tumour stage [n (%)] | 9909 (90) | 234 (39) | <0.001 |
| Clinical nodal status [n (%)] | 2612 (24) | 35 (6) | <0.001 |
| Tumour grade [n (%)] | 273 (2) | 174 (29) |
| Nodal surgery [n (%)] | 1044 (9) | 270 (45) |
| Breast-conserving surgery | 4606 (42) | 205 (34) |
| Mastectomy | 3708 (34) | 311 (52) |
| Nodal surgery | 34 (3) | 28 (5) |
| Nodal irradiation [n (%)] | 130 (1) | 51 (8) |
| **Overall stage [n (%)]** | 10766 (97) | 272 (45) | <0.001 |
| Primary surgery [n (%)] | 290 (3) | 330 (55) |
| Breast-conserving surgery | 6376 (58) | 50 (8) | <0.001 |
| Mastectomy | 4413 (40) | 543 (90) |
| Nodal surgery | 267 (2) | 9 (1) |
| Nodal irradiation [n (%)] | 5487 (50) | 51 (8) | <0.001 |
| **Type of neoadjuvant systemic therapy [n (%)]** | 5825 (51) | 462 (77) |
| Chemotherapy | 2211 (20) | 72 (12) |
| Endocrine therapy | 506 (5) | 17 (3) |
| Missing | 2863 (26) | 510 (85) | <0.001 |

ER = estrogen receptor; HER2 = human epidermal growth factor receptor; SLNB = sentinel lymph node biopsy; ALND = axillary lymph node dissection; NA = not applicable.
additional patient, tumour, and treatment characteristics, demonstrating a marked difference between patients who did and did not receive NAST. As expected, patients in the NAST cohort had more advanced disease: 63% compared with 5% in the no-NAST cohort had cT3 or cT4 disease (\(p < 0.001\)), and 61% compared with just 10% in the no-NAST cohort had clinically node-positive disease (\(p < 0.001\)). Stage III cancers were more common in the NAST cohort than in the no-NAST cohort (55% vs. 3%, \(p < 0.001\)). The patients who received NAST were more aggressive surgery: 90% compared with 40% in the no-NAST cohort underwent mastectomy, and 77% compared with 26% in the no-NAST cohort underwent axillary lymph node dissection (\(p < 0.001\)). Compared with patients having stages I–II disease, patients with stage III cancers were significantly more likely to receive NAST (53% vs. 2%, \(p < 0.001\)).

**Temporal Trends in NAST Use**

Table II shows that use of NAST did not increase during the study period; it remained at 5%–6% per year (\(p = 0.13\)). A statistically significant increase in the use of NAST to 3% from 2% (\(p < 0.001\)) was seen in all stage I–II patients and corresponds to a 50% relative increase in patients treated with NAST to 51% in 2012 from 37% in 2007 (\(p = 0.003\)). We observed no statistical difference in the proportion of stage III patients treated with NAST during the study period (\(p = 0.3\)). On multivariable regression analysis (Table III), year of treatment was not significantly associated with the use of NAST.

**Assessment of Lymph Node Status Before NAST**

Table IV shows that, before NAST, clinical exam was the most frequent method of assessing lymph node status and only a small number of patients underwent pathology assessment. In clinically lymph node–positive patients, a pathology assessment based on a fine-needle aspiration or core biopsy was performed roughly 50% of the time (47%, 42%, and 50% for cN1, cN2, and cN3 respectively). In clinically node-negative patients, 4% underwent sentinel lymph node biopsy (SLNB) before NAST. Axillary staging by methods other than clinical exam alone increased during the study period to 45% in 2010–2012 from 30% in 2007–2009 (\(p < 0.001\), Table V).

**Use of Nodal Irradiation**

Compared with the no-NAST patients, patients treated with NAST were more likely to receive nodal irradiation (85% vs. 27%, \(p < 0.001\), Table I). The use of nodal irradiation differed between the patients with lower-stage (I–II) and higher-stage (III) disease (80% vs. 89% respectively, \(p = 0.002\)). A statistically significant association of increasing use of nodal irradiation increase in clinical nodal stage was evident: 78%, 89%, 90%, and 94% for cN0, cN1, cN2, and cN3 respectively (\(p = 0.002\)). Pathologic nodal status after chemotherapy (yp stage) was not associated with subsequent delivery of nodal irradiation (\(p = 0.80\), Table VI).

**Multivariable Analysis**

To find associations with the use of NAST, a multivariable regression analysis controlling for age, stage, year, bcca

---

**Table II** Use of neoadjuvant systemic therapy, 2007–2012

| Year         | Pts (n) | Overall Proportion of patients who received neoadjuvant systemic therapy [n/N (%)] | Stage I–II Proportion of patients who received neoadjuvant systemic therapy [n/N (%)] | Stage III Proportion of patients who received neoadjuvant systemic therapy [n/N (%)] |
|--------------|---------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 2007 (partial) | 634     | 35 (6) | 0.13 | 13/603 (2) | <0.001 | 22/31 (71) | 0.30 |
| 2008         | 2128    | 96 (5) | 0.13 | 31/1995 (2) | 65/133 (49) |
| 2009         | 2208    | 101 (5) | 0.13 | 36/2093 (2) | 65/115 (56) |
| 2010         | 2385    | 139 (6) | 0.13 | 69/2257 (3) | 70/128 (55) |
| 2011         | 2528    | 147 (6) | 0.13 | 80/2397 (3) | 67/131 (51) |
| 2012 (partial) | 1765   | 84 (5) | 0.13 | 43/1683 (3) | 41/82 (50) |

\(\text{a} \) Data missing for 10 patients.

**Table III** Lymph node assessment before neoadjuvant systemic therapy

| Assessment type      | Pts (n) | Clinical nodal status [n (%)] | \(p\) Value |
|----------------------|---------|-----------------------------|------------|
|                      |         | N0 (n=228)               | N1 (n=267) | N2 (n=69) | N3 (n=26) |
| SLNB                 | 10      | 10 (4)                     | 0          | 0         | 0         | <0.001 |
| Ultrasonography      | 23      | 10 (4)                     | 10 (4)     | 2 (3)     | 1 (4)     |         |
| Clinical only        | 357     | 180 (79)                   | 129 (48)   | 37 (54)   | 11 (42)   |         |
| FNA or core biopsy   | 200     | 28 (12)                    | 128 (48)   | 30 (43)   | 14 (54)   |         |

\(\text{a} \) Data missing for 12 patients.

Pts = patients; SLNB = sentinel lymph node biopsy; FNA = fine-needle aspiration.
facility, tumour characteristics, and use of non-systemic treatment was performed. Increasing age was significantly associated with decreasing use of nast (odds ratio: 0.95 per year; 95% CI: 0.93 to 0.96; p ≤ 0.001). Increased use of nast was associated with increasing clinical tumour and clinical nodal stage and with HER2-positive disease (1.84; 95% CI: 1.4 to 2.4; p < 0.001; Table III).

When a multivariable regression analysis was performed to look at the use of nodal rt in the nast group, clinical T2 [hazard ratio (HR): 6.46; 95% CI: 1.21 to 34.54; p = 0.029], T3 (HR: 9.52; 95% CI: 1.44 to 62.84; p = 0.019), and T4 disease (HR: 16.9; 95% CI: 2.27 to 126.0; p = 0.006), and high grade (HR: 7.4; 95% CI: 1.9 to 28.86; p = 0.004) were predictive of the use of nodal rt. Increasing age (HR: 0.91; 95% CI: 0.85 to 0.98; p = 0.01), estrogen receptor negativity (HR: 0.23; 95% CI: 0.06 to 0.89; p = 0.03), undergoing SLNB (HR: 0.22; 95% CI: 0.6 to 0.89; p = 0.03), having breast-conserving surgery (HR: 0.12; 95% CI: 0.03 to 0.5; p = 0.004), and being treated at centre 2 (HR: 0.11; 95% CI: 0.02 to 0.64; p = 0.014) were found to be predictive of less nodal rt. The remaining variables, including clinical nodal status, pathologic T or N status, lymphovascular space invasion, HER2 status, and year of treatment were not significant (data not shown).

**Survival and Control Analysis**

Patients in the nast and no-nast groups showed statistically significant differences in 5-year OS, LRRFS, and DMFS.

### TABLE IV  Multivariable logistic regression analysis

| Characteristic                  | Receipt of neoadjuvant systemic therapy |
|---------------------------------|----------------------------------------|
| OR*                             | 95% CI | p Value |
| Age of patient (continuous)     | 0.95   | 0.93 to 0.96 | <0.001 |
| Menopausal status               |        |            |
| Postmenopausal                  | Reference |        |
| Premenopausal                   | 0.76   | 0.53 to 1.1 | 0.15   |
| Pregnant                        | 0.22   | 0.02 to 2.5 | 0.22   |
| BCCA centre                     |        |            |
| 1                               | Reference |        |
| 2                               | 0.22   | 0.14 to 0.33 | <0.001 |
| 3                               | 0.55   | 0.39 to 0.78 | 0.001 |
| 4                               | 0.87   | 0.61 to 1.24 | 0.44   |
| 5                               | 0.60   | 0.39 to 0.94 | 0.03   |
| 6                               | 1.83   | 0.24 to 13.87| 0.56   |
| Year of treatment               |        |            |
| 2012                            | Reference |        |
| 2011                            | 1.54   | 0.82 to 2.88 | 0.18   |
| 2010                            | 0.8    | 0.51 to 1.26 | 0.34   |
| 2009                            | 1.04   | 0.67 to 1.6  | 0.88   |
| 2008                            | 1.34   | 0.88 to 2.03 | 0.17   |
| 2007                            | 1.29   | 0.86 to 1.94 | 0.22   |
| Clinical primary tumour stage   |        |            |
| T1                              | Reference |        |
| T2                              | 4.88   | 3.32 to 7.17 | <0.001 |
| T3                              | 48.6   | 31.9 to 73.87| <0.001 |
| T4                              | 225.58 | 140.44 to 362.31| <0.001 |
| Clinical nodal stage            |        |            |
| N0                              | Reference |        |
| N1                              | 3.84   | 2.94 to 5.0  | <0.001 |
| N2                              | 14.0   | 8.14 to 24.17| <0.001 |
| N3                              | 12.69  | 5.58 to 28.82| <0.001 |
| Tumour grade                    |        |            |
| Low (1, 2)                      | Reference |        |
| High (3)                        | 0.95   | 0.72 to 1.25 | 0.71   |
| ER status                       |        |            |
| Positive                        | Reference |        |
| Negative                        | 1.19   | 0.87 to 1.62 | 0.28   |
| HER2 status                     |        |            |
| Negative                        | Reference |        |
| Positive                        | 1.84   | 1.39 to 2.44 | <0.001 |

* A result >1 favours neoadjuvant systemic therapy.

BCCA = BC Cancer Agency; ER = estrogen receptor; HER2 = human epidermal growth factor receptor.

### TABLE V  Method of axillary nodal staging for patients receiving neoadjuvant systemic therapy

| Study period | Pts (n) | Assessment method [n (%)] | p Value |
|--------------|---------|----------------------------|---------|
|              |         | Clinical only (n=357)      |         |
|              |         | Others (n=233)             |         |
| 2007–2009    | 228     | 160 (70)                   | <0.001  |
|              |         | 68 (30)                    |         |
| 2010–2012    | 362     | 197 (54)                   |         |
|              |         | 165 (46)                   |         |

* Data missing for 12 patients.

### TABLE VI  Nodal irradiation in patients receiving neoadjuvant systemic therapy by stage and nodal status

| Variable | Pts (n) | Received nodal radiotherapy [n (%)] | p Value |
|----------|---------|------------------------------------|---------|
| Stage    |         |                                    |         |
| I–II     | 272     | 217 (80)                           | 0.002   |
| III      | 330     | 298 (90)                           |         |
| Nodal status |        |                                    |         |
| Clinical |         |                                    |         |
| N0       | 234     | 182 (78)                           | 0.002   |
| N1       | 270     | 239 (89)                           |         |
| N2       | 70      | 63 (90)                            |         |
| N3       | 28      | 26 (93)                            |         |
| Pathologic |       |                                    |         |
| ypN0     | 264     | 220 (83)                           | 0.80    |
| ypN1     | 176     | 151 (86)                           |         |
| ypN2     | 93      | 82 (88)                            |         |
| ypN3     | 29      | 24 (83)                            |         |
| ypNX     | 40      | 33 (83)                            |         |
estimates: os, 74% (95% CI: 71% to 78%) and 89% (95% CI: 88% to 90%) respectively, \( p < 0.001 \); \( \text{LRRFS} \), 94% (95% CI: 92% to 96%) and 97% (95% CI: 97% to 97%), \( p < 0.001 \); and \( \text{DMFS} \), 73% (95% CI: 70% to 77%) and 92% (95% CI: 91% to 92%), \( p < 0.001 \) (Figure 1). When Cox regression incorporating age, stage, histologic features, and treatment was applied, the HR between the \( \text{NAST} \) and no-\( \text{NAST} \) groups did not reach significance (os HR: 1.15; 95% CI: 0.93 to 1.42; \( p = 0.21 \); \( \text{LRRFS} \) HR: 0.92; 95% CI: 0.61 to 1.4; \( p = 0.71 \); \( \text{DMFS} \) HR: 0.95; 95% CI: 0.76 to 1.18; \( p = 0.62 \)).

In stage III patients, no significant difference for the \( \text{LRRFS} \) at 5 years [90% (95% CI: 86% to 93%) vs. 87% (95% CI: 82% to 91%), \( p = 0.31 \)] or for the \( \text{DMFS} \) [64% (95% CI: 58% to 69%) vs. 61% (95% CI: 55% to 67%), \( p = 0.35 \)] was found between the \( \text{NAST} \) and the no-\( \text{NAST} \) groups [Figure 2(B,C)]. A difference in os at 5 years was seen between the groups: 65% (95% CI: 60% to 70%) in the \( \text{NAST} \) group compared with 55% (95% CI: 49% to 61%) in the no-\( \text{NAST} \) group, \( p = 0.001 \) [Figure 2(A)], although the difference was nonsignificant on multivariable Cox regression analysis when controlling for patient, tumour, and treatment factors (HR: 1.01; 95% CI: 0.79 to 1.47; \( p = 0.64 \)).

**DISCUSSION**

This multicentre population-based study found a 5% rate of \( \text{NAST} \) use for nonmetastatic BCa between 2007 and 2012, while the use of \( \text{NAST} \) in stages I–II patients increased statistically significantly during the study period. Nodal assessment before \( \text{NAST} \) rarely included imaging or pathology confirmation of involvement. Delivery of \( \text{RT} \) included nodal regions in most cases, regardless of the pathologic nodal stage after \( \text{NAST} \).

The incidence of \( \text{NAST} \) in British Columbia is similar to that in other reports, including the reported 3.8% use of \( \text{NAST} \) in 4 large U.S. treatment centres\(^{20}\) and the 8.5% use in another Canadian province\(^{21}\). Use of \( \text{NAST} \) was quite a bit lower than in another American study, which reported a \( \text{NAST} \) rate of 17.4%\(^{22}\). All of those studies demonstrated variability by stage, centre\(^{20}\), surgeon\(^{21}\), and geographic region\(^{22}\), as in our cohort, for whom use of \( \text{NAST} \) varied by cancer centre—a finding showing that, despite widely published guidelines\(^{23,24}\), potential biases based on region and training can affect patient care.

We had hypothesized that use of \( \text{NAST} \) would increase during the study period, as reported by others\(^{21,22}\); however, in our cohort, use of \( \text{NAST} \) was relatively stable. The difference might be explained by our shorter time period (5 years compared with the 8 years used by Mougalian et al.\(^{22}\)) or by significant increases in \( \text{NAST} \) use after 2012 (the period used by Graham et al.\(^{21}\)). Notably, use of \( \text{NAST} \) increased for early-stage disease (I–II), but stayed stable for stage III disease. Given that observation, it is possible that the increase in \( \text{NAST} \) use for early-stage patients was not enough to cause a statistically significant change in the overall use of \( \text{NAST} \), resulting in stable \( \text{NAST} \) use over the period studied.

Since the publication of the NSABP B-18 trial\(^4\), a growing number of reports have described the use of \( \text{NAST} \) to allow for breast conservation and improved cosmetic outcomes\(^3,5,19,25\). In the research community, interest is also growing in the use of \( \text{NAST} \) as a way to evaluate \textit{in vivo}...
A tumour response to chemotherapy and to assess systemic agents that are active against bcA\textsuperscript{26,27}. Given the expanded potential indications for NAST, education of oncologists in its possible uses are needed to ensure that all eligible patients are considered for NAST, while at the same time ensuring that the effects of NAST on other treatment modalities are also considered.

Multiple institutions have proposed approaches to axillary staging and the use of SLNB\textsuperscript{3,14,23,27}. In our population-based cohort, no consistent approach to axillary staging was observed. Clinical examination alone was the most frequent method; however, the use of methods other than clinical exam increased. The rate of clinical assessment alone that we observed is not dissimilar to the 45\% rate reported by Kilbride \textit{et al.}\textsuperscript{27}, despite a standardized nodal staging guideline being in place at their centre. When pathology assessment was performed before NAST in our cohort, the most common method was fine-needle aspiration or core-needle biopsy. The accuracy of those methods has been investigated, and in clinically suspicious lymph nodes, the sensitivity falls into the 60\%–70\% range, with the specificity approaching 100\%\textsuperscript{14,15,27}.

In our cohort, use of SLNB before NAST was low (only 4\% for cN0). The clinically negative axilla poses a challenge in terms of adequate assessment and potentially makes the decision about future nodal RT difficult. A concern with upfront SLNB is delay in the start of systemic treatment. Kilbride \textit{et al.}\textsuperscript{27} reported that, even with SLNB, only 4 weeks elapsed between initial diagnosis and the start of systemic treatment, but whether that timeline is achievable at all centres without directed resources for the purpose is unclear. Some physicians advocate for the use of SLNB only after completion of NAST, but the accuracy of SLNB in that setting is not conclusive. Data from a retrospective analysis\textsuperscript{28} and a meta-analysis\textsuperscript{29} showed that results from SLNB after NAST seem similar to those obtained upfront. However, a large randomized trial investigating SLNB in the NAST setting has cast doubt on the reliability of that observation, concluding that the false-negative rate is greater than 10\% and that results should be interpreted with caution\textsuperscript{30}. The best use of SLNB in the NAST setting has yet to be determined.

Compared with reports emerging from randomized controlled trials\textsuperscript{30–32}, the non-uniform approach to axillary staging seen in our cohort likely reflects the reality of clinical practice and the balance between requesting staging investigations and initiating treatment in a timely fashion. With emerging data suggesting that a pathology assessment of response in lymph nodes might inform the need for nodal irradiation\textsuperscript{16,33}, the importance of adequate initial nodal staging is increasing. At a minimum, fine-needle aspiration should be attempted before NAST\textsuperscript{a} for eligibility to enrol in NSABP B-51/Radiation Therapy Oncology Group 1304 (NCT009353)\textsuperscript{20} and recommended by the U.S. National Comprehensive Cancer Network\textsuperscript{23}.

The use of LR RT after NAST was high (86\%), more frequent in stage III patients, and increased in frequency with increasing clinical nodal stage. Pathologic nodal stage was

\textsuperscript{a} Also see NCT02413320 and NCT02413320 at https://ClinicalTrials.gov.
not associated with the use of nodal rt after nast, which might be attributable to the uncertainty of omitting nodal rt in that setting. Recent randomized trials in the adjuvant setting have shown that patients with 1–3 positive nodes benefit from nodal irradiation, with improved local control and improved distant disease-free survival. However, a meta-analysis and subgroup analysis of the nsabp b-18 and b-27 trials indicate that patients with a pathologic complete response in the axilla have a low risk of lr relapse. That observation has led to the current nsabp b-51/radiation therapy oncology group 1304 (nrg 9353) trial addressing the question of whether nodal rt can be omitted after nodal pathologic complete response with nast. until those results are available (in 2025 or beyond), uncertainty will remain about whether post-nast nodal status can be used to exclude the benefit of regional rt for pathologically positive nodes.

in the present study, 5-year os, lrrfs, and dmfs were not, on multivariable analysis, different for the stage iii patients in the nast and no-nast cohorts. that finding was expected, based on the randomized trial data, and it continues to support the understanding that the timing of chemotherapy does not seem to influence survival outcomes.

the results of our study should be interpreted within the context of its strengths and limitations. given the retrospective nature of the study, we were not fully able to explore physician rationale for prescribing or not prescribing lr rt. additionally, the study examined an era during which nast was not commonly used to enable breast-conserving surgery. before nast, too few patients underwent pathologic axillary staging, and that non-uniform pre-nast axillary staging limits our ability to comment on the effect of nast treatment response, subsequent irradiation, and outcomes. since 2012, the use of nast might have continued to increase; our report might therefore not reflect the most current rates of nast use. however, no level 1 evidence to support a change in use of rt in the setting of nast has been published, and therefore the pattern of rt practice observed here is likely still to be representative of current practice. additionally, our study undertook a large population-based analysis in a jurisdiction with universal health coverage and a single provider of rt services, thus limiting referral and selection bias. it therefore describes the observed prescription pattern of lr rt for bca after nast for all patients referred to the bcca during the study period.

conclusions

our population-based study found a 5% use of nast for bca, with a statistically significant increase in its use in early-stage disease during the study period. most patients received lr rt after nast, even in the context of clinical stage i and ii cancers, independent of pathologic stage after nast. our study likely reflects the current realities of clinical practice and shows that reliance on clinical staging of the axilla results in survival outcomes similar to those reported in the literature. hopefully, future research will provide further guidance about which patients can avoid lr rt after nast and clarity about the most robust method of axillary staging before nast.

acknowledgments

we acknowledge the canadian association of radiation oncology for support through a fellowship grant.

conflict of interest disclosures

we have read and understood current oncology’s policy on disclosing conflicts of interest, and we declare the following interests: tak received fellowship funding from caro while this work was being done. ro has received funding from varian, but not in relation to the present work. the other co-authors have no conflicts of interest to disclose.

author affiliations

*b cancer agency—centre for the north, radiation oncology department, prince george, bc (currently: b cancer agency—sindi alhuwalia hawkins centre for southern interior, kelowna, bc); †university of british columbia, vancouver, bc; ‡sweden gana medical centre, accra, ghana; and § b cancer agency, breast cancer outcomes unit, bc cancer agency–vancouver centre, radiation oncology department, and †bc cancer agency–vancouver centre, medical oncology department, vancouver, bc.

references

1. mamounas ep. neoadjuvant chemotherapy for operable breast cancer: is this the future? clin breast cancer 2003;4(suppl 1):s10–19.
2. sevcikova k, vertakova-krakovska b, spanik s. neoadjuvant treatment in patients with hr+ breast cancer. isrn oncology 2013;2013:362467.
3. santa-maria ca, camp m, cimino-mathews a, harvey s, wright j, stearns v. neoadjuvant therapy for early-stage breast cancer: current practice, controversies, and future directions. oncology (williston park) 2015;29:829–38.
4. fisher b, brown a, mamounas e, et al. effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project b-18. j clin oncol 1997;15:2483–93.
5. schott af, hayes df. defining the benefits of neoadjuvant chemotherapy for breast cancer. j clin oncology 2012;30:1747–9.
6. unicht m, loibl s, bischoff j, et al. lapatinib versus trastuzumab in combination with neoadjuvant anthracycline–taxane-based chemotherapy (geparquinto, ggb 44): a randomised phase 3 trial. lancet oncology 2012;13:135–44.
7. darby s, mcgale p, correia c, et al. on behalf of the early breast cancer trialists’ collaborative group. effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. lancet oncology 2013;14:1707–15.
8. mcgale p, taylor c, correia c, et al. on behalf of the early breast cancer trialists’ collaborative group. effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. lancet 2014;383:2127–35.
9. overgaard m, hanssen ps, overgaard j, et al. postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. danish breast cancer cooperative group 82b trial. n engl j med 1997;337:949–55.
10. ragaz j, jackson sm, le n, et al. adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. n engl j med 1997;337:956–62.
11. overgaard m, jensen mb, overgaard j, et al. postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: danish breast cancer

316 current oncology, vol. 24, no. 5, october 2017 © 2017 multimed inc.
Cooperative Group dbcg 82c randomised trial. *Lancet* 1999;353:1641–8.

12. Poortmans PM, Collette S, Kirkove C, *et al.* on behalf of the www.eortc Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer. *N Engl J Med* 2015;373:317–27.

13. Whelan TJ, Oliveto IA, Levine MN. Regional nodal irradiation in early-stage breast cancer. *N Engl J Med* 2015;373:1878–9.

14. Buchholz TA, Lehman CD, Harris JR, *et al.* Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. *J Clin Oncol* 2008;26:791–7.

15. Garcia-Ortega MJ, Benito MA, Vahamonde EF, Torres PR, Velasco AB, Paredes MM. Pretreatment axillary ultrasonography and core biopsy in patients with suspected breast cancer: diagnostic accuracy and impact on management. *Eur J Radiol* 2011;79:64–72.

16. Mamounas EP, Anderson SJ, Dignam JJ, *et al.* Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. *J Clin Oncol* 2012;30:3960–6.

17. Kuebler HM, Newman LA, Smith TL, *et al.* Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. *J Clin Oncol* 1999;17:460–9.

18. Thomas A, Ohlinger R, Hauschild M, Mustea A, Blohmer JU, Kummel S. Options and limits of surgery after preoperative chemotherapy in breast cancer. *Anticancer Res* 2006;26:1677–82.

19. Peintinger F, Symmans WF, Gonzalez-Angulo AM, *et al.* The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. *Cancer* 2006;107:1248–54.

20. Onitilo AA, Onesti JK, Single RM, *et al.* Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer. *PloS One* 2013;8:e84535.

21. Graham PJ, Brar MS, Foster T, *et al.* Neoadjuvant chemotherapy for breast cancer, is practice changing? A population-based review of current surgical trends. *Ann Surg Oncol* 2015;22:3376–82.

22. Mougalian SS, Soulos PR, Killelea BK, *et al.* Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. *Cancer* 2015;121:2544–52.

23. National Comprehensive Cancer Network (nccn). *NCCN Clinical Practice Guidelines in Oncology: Breast Cancer*. Ver. 2.2016. Fort Washington, PA: nccn; 2016. [Current version available online at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (free registration required); cited 16 August 2016]

24. BC Cancer Agency. Health Professionals > Professional Resources > Cancer Management Guidelines > Breast > Breast [web resource]. Ch. 6. Management. Pt. 70: Neoadjuvant Therapy. Vancouver, BC: bcca; 2016. [Available at: http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines/breast/breast#7-Neoadjuvant-Therapy; cited 16 August 2016]

25. Chen AM, Meric-Bernstam F, Hunt KK, *et al.* Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. *J Clin Oncol* 2004;22:2303–12.

26. Magbanua MJ, Wold DM, Yau C, *et al.* Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. *Breast Cancer Res* 2015;17:73.

27. Kilbride KE, Lee MC, Nees AV, *et al.* Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. *Ann Surg Oncol* 2008;15:3252–8.

28. Mamounas EP, Brown A, Anderson S, *et al.* Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol* 2005;23:2694–702.

29. Xing Y, Foy M, Cox DD, Kuebler HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. *Br J Surg* 2006;93:539–46.

30. Boughhey IC, Suman VJ, Mittendorf EA, *et al.* Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the acsosog.Z1071 (Alliance) clinical trial. *JAMA* 2013;310:1455–61.

31. Haffty BG, McCall LM, Balmman KV, *et al.* Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: results from acsosog.Z1071 (Alliance). *Int J Radiat Oncol Biol Phys* 2016;94:493–502.

32. von Minckwitz G, Untch M, Blohmer JU, *et al.* Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol* 2012;30:1796–804.

33. Rastogi P, Anderson SJ, Bear HD, *et al.* Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. *J Clin Oncol* 2008;26:778–85.

34. Bear HD, Anderson S, Smith RE, *et al.* Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol* 2006;24:2019–27.